title: Potential for control of detrusor smooth muscle spontaneous rhythmic contraction by cyclooxygenase products released by interstitial cells of Cajal.
abstract: Interstitial cells of Cajal (ICCs) have been identified as pacemaker cells in the upper urinary tract and urethra, but the role of ICCs in the bladder remains to be determined. We tested the hypotheses that ICCs express cyclooxygenase (COX), and that COX products (prostaglandins), are the cause of spontaneous rhythmic contraction (SRC) of isolated strips of rabbit bladder free of urothelium. SRC was abolished by 10 microM indomethacin and ibuprofen (non-selective COX inhibitors). SRC was concentration-dependently inhibited by selective COX-1 (SC-560 and FR-122047) and COX-2 inhibitors (NS-398 and LM-1685), and by SC-51089, a selective antagonist for the PGE-2 receptor (EP) and ICI-192,605 and SQ-29,548, selective antagonists for thromboxane receptors (TP). The partial agonist/antagonist of the PGF-2alpha receptor (FP), AL-8810, inhibited SRC by approximately 50%. Maximum inhibition was approximately 90% by SC-51089, approximately 80-85% by the COX inhibitors and approximately 70% by TP receptor antagonists. In the presence of ibuprofen to abolish SRC, PGE-2, sulprostone, misoprostol, PGF-2alpha and U-46619 (thromboxane mimetic) caused rhythmic contractions that mimicked SRC. Fluorescence immunohistochemistry coupled with confocal laser scanning microscopy revealed that c-Kit and vimentin co-localized to interstitial cells surrounding detrusor smooth muscle bundles, indicating the presence of extensive ICCs in rabbit bladder. Co-localization of COX-1 and vimentin, and COX-2 and vimentin by ICCs supports the hypothesis that ICCs were the predominant cell type in rabbit bladder expressing both COX isoforms. These data together suggest that ICCs appear to be an important source of prostaglandins that likely play a role in regulation of SRC. Additional studies on prostaglandin-dependent SRC may generate opportunities for the application of novel treatments for disorders leading to overactive bladder.
authors.affiliation: Department of Surgery, Urology Division, Virginia Commonwealth University School of Medicine, VA 23298-0614, USA.
authors.forename: Clinton
authors.initials: C
authors.lastname: Collins
authors.forename: Adam P
authors.initials: AP
authors.lastname: Klausner
authors.forename: Benjamin
authors.initials: B
authors.lastname: Herrick
authors.forename: Harry P
authors.initials: HP
authors.lastname: Koo
authors.forename: Amy S
authors.initials: AS
authors.lastname: Miner
authors.forename: Scott C
authors.initials: SC
authors.lastname: Henderson
authors.forename: Paul H
authors.initials: PH
authors.lastname: Ratz
mesh_terms: D000818:Animals; D051545:Cyclooxygenase 1 / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D005260:Female; D006834:Hydrazines / Q000494:pharmacology; D007052:Ibuprofen / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D056885:Interstitial Cells of Cajal; D009119:Muscle Contraction; D009130:Muscle, Smooth / Q000378:metabolism*; D010077:Oxazepines / Q000494:pharmacology; D011453:Prostaglandins / Q000378:metabolism; D011817:Rabbits; D001743:Urinary Bladder / Q000378:metabolism*; D014746:Vimentin / Q000378:metabolism
chemical_list: D016861:Cyclooxygenase Inhibitors; D006834:Hydrazines; D010077:Oxazepines; D011453:Prostaglandins; D014746:Vimentin; C086836:SC 51089; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D007052:Ibuprofen; D007213:Indomethacin